What is the guideline-directed medical therapy for hypertension and heart failure?

Guideline-Directed Medical Therapy for Hypertension and Heart Failure

For patients with both hypertension and heart failure with reduced ejection fraction (HFrEF), initiate quadruple therapy with ACE inhibitors (or ARBs if intolerant), evidence-based beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, targeting blood pressure <130/80 mmHg while titrating heart failure medications to trial-proven doses regardless of blood pressure levels. 1, 2, 3, 4

Heart Failure with Reduced Ejection Fraction (HFrEF)

Core Quadruple Therapy (All Class I Recommendations)

ACE Inhibitors or ARBs:

• Start ACE inhibitors first-line for all symptomatic HFrEF patients 1, 2, 3
• If ACE inhibitor intolerant (typically due to cough or angioedema), substitute with ARB 1, 3
• Titrate to trial-proven doses (not just blood pressure control) 1, 2
• Critical caveat: Monitor creatinine and potassium closely; acceptable for creatinine to rise up to 30% or potassium up to 5.0-5.5 mEq/L 3

Evidence-Based Beta-Blockers:

• Use only bisoprolol, carvedilol, or metoprolol succinate (sustained-release) 1, 3
• Start at very low doses and uptitrate every 1-2 weeks if tolerated 5
• Continue even if blood pressure drops to 90-100 mmHg systolic, provided patient is asymptomatic 1
• Do not discontinue for asymptomatic hypotension—reduce other vasodilators first 5

Mineralocorticoid Receptor Antagonists (MRAs):

• Spironolactone 12.5-25 mg daily for NYHA class II-IV patients with LVEF ≤35% 1, 3
• Requires creatinine ≤2.5 mg/dL (men) or ≤2.0 mg/dL (women) and potassium <5.0 mEq/L 3
• Check potassium and creatinine at 4-6 days, then regularly 5
• Stop if potassium ≥5.5 mEq/L or reduce dose by 50% 5

SGLT2 Inhibitors:

• Add dapagliflozin or empagliflozin regardless of diabetes status 4, 6
• Provides mortality and hospitalization benefit independent of blood pressure lowering 4, 6
• Can be initiated even with systolic BP 90-100 mmHg 4

Additional Therapies for Blood Pressure Control

Diuretics:

• Loop diuretics (furosemide, torsemide, bumetanide) for volume control—Grade D evidence for mortality but essential for symptoms 1, 3
• Thiazides for blood pressure control if needed beyond loop diuretics 1
• Avoid thiazides if eGFR <30 mL/min; use loop diuretics instead 7

Dihydropyridine Calcium Channel Blockers:

• Add amlodipine or felodipine if blood pressure remains uncontrolled on above therapies 1, 2
• Never use short-acting nifedipine 1
• Avoid non-dihydropyridine CCBs (diltiazem, verapamil) in HFrEF—they worsen heart failure 8

Critical Monitoring Points

When combining ACE inhibitors and ARBs (only if blood pressure uncontrolled):

• Acceptable in HFrEF for blood pressure control 1, 2
• Monitor closely for hypotension, hyperkalemia, and worsening renal function 1, 2
• Do NOT combine in patients with prior stroke or coronary disease without HFrEF 2

Heart Failure with Preserved Ejection Fraction (HFpEF)

Primary Therapy

SGLT2 Inhibitors:

• First-line therapy with Class I recommendation for HFpEF 7, 9, 4
• Reduces heart failure hospitalizations (HR 0.79,95% CI 0.67-0.93) 10
• Provides modest systolic BP reduction (-2.3 mmHg) 10

Blood Pressure Control:

• Target <130/80 mmHg (<140/80 in elderly) 7, 9
• RAS blockers (ACE inhibitors or ARBs) are first-line antihypertensives 7, 11
• Add CCBs and diuretics as needed 7
• Spironolactone may be considered for additional benefit 11

Angiotensin Receptor-Neprilysin Inhibitors (ARNi):

• Sacubitril-valsartan can be used as alternative to ACE inhibitors/ARBs in HFpEF 7

Hypertension Without Heart Failure (Prevention)

Blood Pressure Targets

• <130/80 mmHg for most patients 7, 9, 12
• <140/80 mmHg acceptable in elderly patients 7

Initial Drug Selection (AB/CD Algorithm)

For patients <55 years or with diabetes:

• Start with ACE inhibitor or ARB (or beta-blocker if post-MI/angina) 8

For patients ≥55 years or Black patients:

• Start with calcium channel blocker or thiazide diuretic 8

Second-line combinations:

• ACE inhibitor/ARB + CCB or thiazide 8
• Avoid ACE inhibitor + ARB combination in hypertension without HFrEF 1

Compelling Indications

Post-Myocardial Infarction:

• ACE inhibitors + beta-blockers mandatory 1, 8
• Add aldosterone antagonists if LVEF ≤40% or symptomatic 3

Coronary Artery Disease:

• Beta-blockers for stable angina 1
• ACE inhibitors or ARBs for all patients 1
• Consider ACE inhibitor + dihydropyridine CCB over ACE inhibitor + diuretic in high-risk patients 1

Post-Stroke:

• ACE inhibitor + thiazide diuretic combination preferred 2
• Target <130/80 mmHg after acute phase 2
• Avoid ACE inhibitor + ARB combination 2

Practical Titration Strategy

1. Start ACE inhibitor (or ARB if intolerant) at low dose
2. Add beta-blocker at very low dose after 1-2 weeks
3. Add MRA once beta-blocker stable (if HFrEF with NYHA II-IV)
4. Add SGLT2 inhibitor (can be started simultaneously with other agents)
5. Uptitrate each medication to target doses every 1-2 weeks
6. Add diuretics for volume control as needed
7. Add CCB only if blood pressure remains >130/80 mmHg despite above therapies

Key principle: In HFrEF, prioritize uptitration of heart failure medications to trial-proven doses over blood pressure targets—these medications improve mortality even with systolic BP 90-110 mmHg 1, 2, 13, 14

Common Pitfalls to Avoid

• Never stop beta-blockers for asymptomatic hypotension—reduce other vasodilators first 5
• Never use non-dihydropyridine CCBs in HFrEF—they worsen outcomes 8
• Never combine ACE inhibitor + ARB in coronary disease or stroke without HFrEF—increases harm 1, 2
• Never use hydralazine or minoxidil for left ventricular hypertrophy—they worsen remodeling 2
• Never withhold MRAs solely for potassium 5.0-5.5 mEq/L—reduce dose by 50% instead 3, 5